Description: Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Home Page: www.iovance.com
0JDK Technical Analysis
825 Industrial Road
San Carlos,
CA
94070
United States
Phone:
650 260 7120
Officers
| Name | Title |
|---|---|
| Dr. Frederick G. Vogt Esq., J.D., Ph.D. | Interim CEO, President, General Counsel, Corporate Secretary & Director |
| Mr. Jean-Marc Bellemin M.B.A. | CFO, Principal Accounting Officer & Treasurer |
| Dr. Igor P. Bilinsky Ph.D. | Chief Operating Officer |
| Dr. Friedrich Graf Finckenstein M.D. | Chief Medical Officer |
| Ms. Sara Pellegrino | Vice President of Investor Relations & Public Relations |
| Ms. Tracy Winton | Executive Vice President of Human Resources |
| Mr. Howard B. Johnson M.B.A. | Chief Business Officer |
| Dr. Raj K. Puri M.D., Ph.D. | Chief Regulatory Officer |
| Mr. Brian Shew M.B.A. | Senior VP & Head of Digital and Information Technology |
| Mr. Kevin Smyth | Executive Vice President of Quality |
Exchange: LSE
Country: GB : United Kingdom of Great Britain and Northern Ireland
Currency: US Dollar ($)
| GIC Sector: | Industrials |
|---|---|
| GIC Group: | Commercial & Professional Services |
| GIC Industry: | Commercial Services & Supplies |
| GIC Sub-Industry: | Environmental & Facilities Services |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 11.8771 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 557 |